连续性肾脏替代治疗与急性肝衰竭患者血氨水平降低及死亡率下降相关
这项多中心队列研究基于美国急性肝衰竭研究组登记库1998年1月至2016年12月的连续急性肝衰竭患者数据,发现入院时血氨中位数较高与3-4级肝性脑病及21天死亡相关。在340例有连续血氨检测的患者中,连续性肾脏替代治疗(CRRT)与血氨降低及21天无移植生存改善相关,而间断性肾脏替代治疗(IRRT)则与21天无移植全因死亡率增加相关。
要点
- 入院血氨中位数较高与3-4级肝性脑病及21天神经性或全因死亡相关。
- 第1至3天,CRRT组血氨中位数下降38%,IRRT组下降23%,无RRT组下降19%。
- 调整混杂因素后,CRRT与21天无移植全因死亡率降低相关(OR 0.47,95%CI 0.26-0.82),IRRT与死亡率增加相关(OR 1.68,95%CI 1.04-2.72)。
核心结论
- 在大型急性肝衰竭患者队列中,高氨血症与高级别肝性脑病及较差的21天无移植生存相关。
- CRRT与血清氨水平降低及21天无移植生存改善相关。
研究设计与样本
- 多中心队列研究,纳入美国急性肝衰竭研究组登记库1998年1月至2016年12月的连续急性肝衰竭患者。
- 分析氨与肝性脑病及21天无移植生存的关联(n=1,186)。
- 分析肾脏替代治疗对研究入组后前3天血氨的影响(n=340)及对21天无移植生存的影响(n=1,186)。
主要发现
- 入院血氨中位数较高与3-4级肝性脑病相关(116 vs. 83 μmol/L)。
- 入院血氨中位数较高与第21天神经性死亡(181 vs. 90 μmol/L)及全因死亡(114 vs. 83 μmol/L)相关,所有P < 0.001。
- 在340例有连续血氨检测的患者中,61例(18%)接受CRRT,59例(17%)接受IRRT,220例(65%)前2天未接受RRT。
- 第1至3天,CRRT组血氨中位数下降38%,IRRT组下降23%,无RRT组下降19%;与无RRT相比,CRRT组血氨降低显著(P = 0.007),IRRT组不显著(P = 0.75)。
- 调整入组年份、年龄、病因和疾病严重程度后,CRRT与21天无移植全因死亡率降低相关(OR 0.47,95%CI 0.26-0.82),IRRT与死亡率增加相关(OR 1.68,95%CI 1.04-2.72)。
临床怎么用
- 作者结论指出,在高氨血症的急性肝衰竭患者中,CRRT与血清氨水平降低及21天无移植生存改善相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hyperammonemia has been associated with intracranial hypertension and mortality in patients with acute liver failure (ALF). We evaluated the effect of renal replacement therapy (RRT) on serum ammonia level and outcomes in ALF. This was a multicenter cohort study of consecutive ALF patients from the United States ALF Study Group registry between January 1998 and December 2016. First, we studied the association of ammonia with hepatic encephalopathy (HE) and 21-day transplant-free survival (TFS; n = 1,186). Second, we studied the effect of RRT on ammonia for the first 3 days post study admission (n = 340) and on 21-day TFS (n = 1,186). Higher admission (n = 1,186) median ammonia level was associated with grade 3-4 HE (116 vs. 83 μmol/L) and mortality at day 21 attributed to neurological (181 vs. 90 μmol/L) and all causes (114 vs. 83 μmol/L; P < 0.001 for all). Among 340 patients with serial ammonia levels, 61 (18%) were on continuous RRT (CRRT), 59 (17%) were on intermittent RRT (IRRT), and 220 (65%) received no RRT for the first 2 days. From days 1 to 3, median ammonia decreased by 38%, 23%, and 19% with CRRT, IRRT, and no RRT, respectively. Comparing to no RRT use, whereas ammonia reduction with CRRT was significant (P = 0.007), with IRRT it was not (P = 0.75). After adjusting for year of enrollment, age, etiology, and disease severity, whereas CRRT (odds ratio [OR], 0.47 [95% confidence interval {CI}, 0.26-0.82]) was associated with reduction in 21-day transplant-free all-cause mortality, IRRT (OR, 1.68 [95% CI, 1.04-2.72]) was associated with an increase. Conclusion: In a large cohort of ALF patients, hyperammonemia was associated with high-grade HE and worse 21-day TFS. CRRT was associated with a reduction in serum ammonia level and improvement of 21-day TFS. (Hepatology 2018;67:711-720).
引用
- Cardoso FS, Gottfried M, Tujios S, et al. Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure. Hepatology. 2017. PMID: 28859230. doi:10.1002/hep.29488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。